First commercially available blood test for endometriosis This new test offers clinicians a tool to detect endometriosis in patients whose lesions may be missed by standard imaging, helping address years-long delays in diagnosis. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/first-commercially-available-blood-test-for-endometriosis-17094?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--L2v_xFxrxrNEE4wbeNp0k_mDXY_-zmY4RFXdmkYcOylRf627E2MMOwifqSjhNz5Kcn_rP8_44SWH2hGq0tAomQiMKDA&_hsmi=419534051&utm_content=419534051&utm_source=hs_email Endometriosis is a chronic neuroinflammatory disorder affecting over 190 million women worldwide. Characterized by the growth of endometrial-like tissue outside the uterus, the condition manifests as peritoneal, ovarian, or deep lesions, most commonly in the pelvis. Patients experience persistent pelvic pain, often worse during menstruation, as well as fatigue, gastrointestinal and urinary symptoms, mood disorders, and in many cases, infertility. Studies estimate that 30-50 percent of patients with endometriosis face difficulties conceiving.